EATG » Hepatitis

Hepatitis

Rapid risk assessment: Hepatitis A outbreak in the EU/EEA, 3rd update

Rapid risk assessment: Hepatitis A outbreak in the EU/EEA mostly affecting men who have sex with men, 3rd update, 28 June 2017 Executive summary Since June 2016, 1 500 confirmed…

Treatment benefits patients with thalassaemia and HCV

Many individuals with the blood disorder thalassaemia also carry the hepatitis C virus (HCV) due to contaminated transfusions before 1990. Due to the co-existence of iron overload (from repeated blood…

WHO advises on the use of multidisease testing devices for TB, HIV and hepatitis

Geneva, 26 June 2017 – The World Health Organization (WHO) released a new information note on “Considerations for adoption and use of multidisease testing devices in integrated laboratory networks”. The…

EASL criticizes Cochrane Review of DAAs for HCV

In a response to the Cochrane Group Review entitled "Direct acting antivirals for chronic hepatitis C," the European Association for the Study of the Liver (EASL) released a statement pointing…

Scotland: Charity calls for new focus to combat hepatitis C

A charity has called for greater efforts to eliminate hepatitis C (HCV) from Scotland. There are about 37,000 people living with the virus - but campaigners say as many again…

Full access to hepatitis C treatment in Switzerland

The Federal Office of Public Health has announced that it will make the hepatitis C drug Zepatier available to all patients from July 1. The 12-week treatment costs CHF31,000 ($31,952)…

Clinical effects of antivirals for hepatitis C: context is critical

An article published in The Guardian on June 8, 2017, led with the startling headline that “‘Miracle’ hepatitis C drugs costing £30k per patient ‘may have no clinical effect’”. The…

Interferon-based SVR in HCV reduced risk for extrahepatic manifestations

Sustained virologic response following interferon-based antiviral therapy in patients with hepatitis C reduced the risk for extrahepatic manifestations, according to results of a recently published study. The researchers suggested this…

New pan-genotypic hepatitis C drug combinations recommended for approval in the European Union

Two new pan-genotypic direct-acting antiviral combinations have received positive opinions from the scientific committee of the European Medicines Agency and should receive European Union marketing approval in next few months,…

AASLD expresses concern for Cochrane Review of DAAs

AASLD and IDSA would like to express our serious concerns regarding the recent Cochrane Group Review concluding that there is a lack of valid evidence supporting the benefit of direct…